RECRUITING

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial evaluates the treatment response of colorectal cancer that has spread to the liver (liver metastases) using intravoxel incoherent motion diffusion weighted imaging (IVIM DWI). IVIM DWI is new kind of imaging scan that may help measure changes in disease before and after chemotherapy in patients with colorectal liver metastases.

Official Title

Evaluation of Treatment Response of Colorectal Cancer Liver Metastases with Intravoxel Incoherent Motion Diffusion Weighted Imaging

Quick Facts

Study Start:2020-08-12
Study Completion:2026-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04796818

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with treatment-naive resectable CLM, who will start chemotherapy with oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with 5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent
  2. * Patients with at least 1 colorectal liver metastasis measuring at least 1 cm
  3. * Patients with anticipated follow-up before and after surgery at MD Anderson
  1. * Patients who have already received preoperative chemotherapy for the CLM or will undergo radiation therapy, ablative therapies, or other non-surgical therapies directed at the liver
  2. * Patients allergic to gadolinium
  3. * Patients with pacemakers
  4. * Greater than 400 pounds in weight

Contacts and Locations

Study Contact

Priya R Bhosale
CONTACT
713-792-0221
priya.bhosale@mdanderson.org

Principal Investigator

Priya R Bhosale
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Priya R Bhosale, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-08-12
Study Completion Date2026-01-31

Study Record Updates

Study Start Date2020-08-12
Study Completion Date2026-01-31

Terms related to this study

Additional Relevant MeSH Terms

  • Metastatic Colorectal Carcinoma
  • Metastatic Malignant Neoplasm in the Liver
  • Resectable Colorectal Carcinoma
  • Stage IV Colorectal Cancer AJCC V8
  • Stage IVA Colorectal Cancer AJCC V8
  • Stage IVB Colorectal Cancer AJCC V8
  • Stage IVC Colorectal Cancer AJCC V8